Skip to main content
. 2018 Dec 4;41(2):939–953. doi: 10.3892/or.2018.6901

Figure 2.

Figure 2.

Correlation between miRNA-126-3p and miRNA-126-5p and clinical pathological parameters based on RT-qPCR data. (A) Expression of miRNA-126-3p in early (I–II) and late (III–IV) TNM stages of LUAD (4.140±2.583 vs. 3.025±1.527, P<0.001). (B) ROC curve of miRNA-126-3p for TNM stages of LUAD (AUC=0.608, P=0.039). (C) Expression of miRNA-126-5p in samples with vascular invasion and samples without vascular invasion (3.045±1.544 vs. 4.814±2.657, P<0.001). (D) ROC cure of miRNA-126-5p for vascular invasion of LUAD (AUC=0.693, P=0.002). (E) Expression of miRNA-126-5p in samples with LNM and samples without LNM (3.671±2.090 vs. 5.142±2.713, P=0.002). (F) ROC of miRNA-126-5p for LNM of LUAD (AUC=0.672, P=0.003). (G) Expression of miRNA-126-5p in early TNM stage (I–II) and later TNM stage (III–IV) of LUAD (4.923±2.700 vs. 3.769±2.233, P=0.024). (H) ROC of miRNA-126-5p for TNM stage of LUAD (AUC=0.625, P=0.032). LUAD, lung adenocarcinoma; AUC, area under the receiver operating characteristic (ROC) curve.